Evidence map›Paper›PMID 35689478›Full record

Trial reportSchizophrenia bulletin2022

Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial.

Delbert G Robinson, Nina R Schooler, Patricia Marcy, Robert D Gibbons, C Hendricks Brown, Majnu John, Kim T Mueser, David L Penn, Robert A Rosenheck, Jean Addington and 12 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Schizophrenia bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Delbert G RobinsonDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.ORCID 0000-0001-6606-4507
Nina R SchoolerDepartment of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY, USA.
Patricia MarcyVanguard Research Group, Glen Oaks, NY, USA.
Robert D GibbonsCenter for Health Statistics, University of Chicago, Chicago, IL, USA.
C Hendricks BrownDepartments of Psychiatry and Behavioral Sciences, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Majnu JohnThe Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA.
Kim T MueserCenter for Psychiatric Rehabilitation, Boston University, Boston, MA, USA.
David L PennDepartment of Psychology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Robert A RosenheckDepartment of Psychiatry, Yale Medical School, New Haven, CT,USA.
Jean AddingtonDepartment of Psychiatry, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Mary F BrunetteDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Christoph U CorrellDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Sue E EstroffDepartment of Social Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Piper S Mayer-KalosDepartment of Psychiatry & Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN, USA.
Jennifer D GottliebDivision of Population Behavioral Health Innovation and Harvard Medical School, Department of Psychiatry, Cambridge Health Alliance, Cambridge, MA, USA.
Shirley M GlynnSemel Institute of Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
David W LyndeDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Susan GingerichDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Ronny PipesDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Alexander L MillerDepartment of Psychiatry and Behavioral Sciences San Antonio, UT Health San Antonio, TX, USA.
Joanne B SevereDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
John M KaneDepartments of Psychiatry and of Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS HHSN-271-2009-00019C
6 · The paper itself

Abstract

To examine long-term effects of early intervention services (EIS) for first-episode psychosis, we compared Heinrichs-Carpenter Quality of Life (QLS) and Positive and Negative Syndrome Scale (PANSS) scores and inpatient hospitalization days over 5 years with data from the site-randomized RAISE-ETP trial that compared the EIS NAVIGATE (17 sites; 223 participants) and community care (CC) (17 sites; 181 participants). Inclusion criteria were: age 15-40 years; DSM-IV diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified; first psychotic episode; antipsychotic medication taken for ≤6 months. NAVIGATE-randomized participants could receive NAVIGATE from their study entry date until NAVIGATE ended when the last-enrolled NAVIGATE participant completed 2 years of treatment. Assessments occurred every 6 months. 61% of participants had assessments conducted ≥2 years; 31% at 5 years. Median follow-up length was CC 30 months and NAVIGATE 38 months. Primary analyses assumed data were not-missing-at-random (NMAR); sensitivity analyses assumed data were missing-at-random (MAR). MAR analyses found no significant treatment-by-time interactions for QLS or PANSS. NMAR analyses revealed that NAVIGATE was associated with a 13.14 (95%CI:6.92,19.37) unit QLS and 7.73 (95%CI:2.98,12.47) unit PANSS better improvement and 2.53 (95%CI:0.59,4.47) fewer inpatient days than CC (all comparisons significant). QLS and PANSS effect sizes were 0.856 and 0.70. NAVIGATE opportunity length (mean 33.8 (SD = 5.1) months) was not associated (P = .72) with QLS outcome; duration of untreated psychosis did not moderate (P = .32) differential QLS outcome. While conclusions are limited by the low rate of five-year follow-up, the data support long-term benefit of NAVIGATE compared to community care.

Indexed as

Antipsychotic AgentsPsychotic DisordersSchizophreniaAdolescentAdultDiagnostic and Statistical Manual of Mental DisordersHumansQuality of LifeYoung AdultAntipsychotic Agentscoordinated specialty careearly intervention servicesfirst episode psychosisfollow-upschizophrenia

Identifiers

PMID35689478
PMCPMC9434430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.